Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.53 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25567577 | 0.83 | KMT2A (0.60) | LMNAHPGDKMT2AALDH1A1RAB9A | |
| SCHEMBL1274285 | 0.83 | LMNA (0.68) | LMNAHPGDKMT2AHTTALDH1A1 | |
| SCHEMBL1709338 | 0.83 | HPGD (0.70) | LMNAHPGDKMT2AHTTALDH1A1 | |
| SCHEMBL2530016 | 0.82 | KMT2A (0.63) | LMNAHPGDKMT2AHTTALDH1A1 | |
| SCHEMBL26097558 | 0.82 | LMNA (0.62) | LMNAHPGDKMT2AHTTALDH1A1 | |
| SCHEMBL9431727 | 0.81 | KMT2A (0.63) | HPGDKMT2AALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL7126303 | 0.81 | GAA (0.63) | LMNAHPGDKMT2AHTTALDH1A1 | |
| SCHEMBL4599033 | 0.81 | LMNA (0.70) | LMNAHPGDKMT2AHTTALDH1A1 | |
| SCHEMBL28313230 | 0.80 | HPGD (0.81) | LMNAHPGDKMT2AHTTALDH1A1 | |
| SCHEMBL20740269 | 0.79 | LMNA (0.68) | LMNAHPGDKMT2AHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | disclosed |
| WO-2021216812-A1 | GALACTOKINASE INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | GALK1, GCK, GCKR | LMNA 1846/4885HPGD 2300/4885KMT2A 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.